



## Solosec® (secnidazole) – Expanded indication

- On January 26, 2022, the FDA approved Lupin Pharmaceuticals' [Solosec \(secnidazole\)](#), for the treatment of:
  - Bacterial vaginosis in female patients 12 years of age and older
  - Trichomoniasis caused by *Trichomonas vaginalis* in patients 12 years of age and older. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent reinfection.
- Solosec was previously approved for these indications in adult patients only.
- The approval of Solosec for the expanded indication for bacterial vaginosis was supported by evidence from an open-label safety study in 40 pediatric female patients with bacterial vaginosis and evidence from adequate and well-controlled studies in adult women.
- The approval of Solosec for the expanded indication for trichomoniasis was based on the extrapolation of clinical trial data from adult women with trichomoniasis, four open-label studies in males with trichomoniasis, and an open-label safety study in pediatric female patients with bacterial vaginosis.
- The recommended dosage of Solosec for the treatment of bacterial vaginosis in female patients 12 years of age and older is a single 2-gram packet of granules taken once orally, without regard to the timing of meals.
- The recommended dosage of Solosec for the treatment of trichomoniasis in patients 12 years of age and older is a single 2-gram packet of granules taken once orally, without regard to the timing of meals. Since trichomoniasis is a sexually transmitted disease, sexual partners should be treated with the same dose and at the same time.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.